The VectorGen Approach
Our vehicle will introduce genetic material through a vector that will utilize a unique auto-regulating mechanism, giving it the ability to turn itself on or off dependent upon viral presence in the cell. This represents a breakthrough platform technology that will result in novel product(s) with significant social and commercial impact.
Our primary target is HIV.
We will pursue a research program to develop a delivery vehicle for therapeutic genetic material for the treatment or cure of HIV, as follows:
1)Engineer a genetic construct to turn on expression of the therapeutic molecule in the presence of infectious virus
2)Incorporate the construct into a viral-based vector
3)Integrate the vector’s cargo into a specific site on a specific human chromosome, free of the risk of oncogenic transformation
4)Destabilize assembly of the HIV virus using the vector-encoded, therapeutic molecule
5)Auto-regulate the vector’s replication to shut it down upon elimination of the threatening virus
The ultimate commercial product will be a single-dose application that confers lasting protection against HIV infection for persons who are uninfected as well as those already infected. This is a significant advance over traditional vaccines that can only protect the uninfected.
You can learn more about our overall approach, from the research to the business end, by visiting our Business Plan page.